These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

985 related items for PubMed ID: 19038426

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oncological outcomes of hormonal therapy with a gonadotropin-releasing hormone agonist combined with a steroidal or non-steroidal antiandrogen in patients with prostate cancer.
    Igawa T, Tsurusaki T, Nomata K, Hayashi M, Furukawa M, Sakai H.
    Anticancer Res; 2014 Apr; 34(4):1983-8. PubMed ID: 24692735
    [Abstract] [Full Text] [Related]

  • 5. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M.
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E, Scandinavian Prostatic Cancer Group-5 Trial Study.
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [Abstract] [Full Text] [Related]

  • 8. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 9. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [Abstract] [Full Text] [Related]

  • 10. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW, Salup R, Patterson SG, Jacobsen PB.
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [Abstract] [Full Text] [Related]

  • 11. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 12. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [Abstract] [Full Text] [Related]

  • 13. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 14. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 15. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 16. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 17. Bicalutamide-associated fulminant hepatotoxicity.
    O'Bryant CL, Flaig TW, Utz KJ.
    Pharmacotherapy; 2008 Aug; 28(8):1071-5. PubMed ID: 18657023
    [Abstract] [Full Text] [Related]

  • 18. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.